I-Tech AB (ITECH.ST)
SEK 54.5
(-1.8%)
SEK 54.5
(-1.8%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 16.2 Million SEK | 72.93% |
| 2022 | 9.37 Million SEK | -7.99% |
| 2021 | 10.18 Million SEK | -24.98% |
| 2020 | 13.57 Million SEK | -31.83% |
| 2019 | 19.91 Million SEK | -3.07% |
| 2018 | 20.54 Million SEK | -10.57% |
| 2017 | 22.97 Million SEK | -11.24% |
| 2016 | 25.88 Million SEK | 112.13% |
| 2015 | 12.2 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 20.65 Million SEK | 55.43% |
| 2024 Q1 | 18.29 Million SEK | 12.92% |
| 2024 Q2 | 13.28 Million SEK | -27.39% |
| 2023 Q4 | 16.2 Million SEK | 3.57% |
| 2023 FY | 16.2 Million SEK | 72.93% |
| 2023 Q1 | 12.08 Million SEK | 28.95% |
| 2023 Q2 | 11.73 Million SEK | -2.93% |
| 2023 Q3 | 15.64 Million SEK | 33.39% |
| 2022 Q4 | 9.37 Million SEK | -14.37% |
| 2022 FY | 9.37 Million SEK | -7.99% |
| 2022 Q1 | 10.49 Million SEK | 2.99% |
| 2022 Q2 | 12.91 Million SEK | 23.11% |
| 2022 Q3 | 10.94 Million SEK | -15.26% |
| 2021 Q1 | 16.68 Million SEK | 22.9% |
| 2021 FY | 10.18 Million SEK | -24.98% |
| 2021 Q4 | 10.18 Million SEK | -33.59% |
| 2021 Q3 | 15.33 Million SEK | 0.91% |
| 2021 Q2 | 15.19 Million SEK | -8.91% |
| 2020 Q2 | 16.13 Million SEK | -11.77% |
| 2020 Q3 | 15.29 Million SEK | -5.18% |
| 2020 Q4 | 13.57 Million SEK | -11.24% |
| 2020 Q1 | 18.28 Million SEK | -8.19% |
| 2020 FY | 13.57 Million SEK | -31.83% |
| 2019 FY | 19.91 Million SEK | -3.07% |
| 2019 Q2 | 16.86 Million SEK | -21.46% |
| 2019 Q4 | 19.91 Million SEK | -1.81% |
| 2019 Q3 | 20.28 Million SEK | 20.23% |
| 2019 Q1 | 21.47 Million SEK | 4.55% |
| 2018 Q3 | 17.33 Million SEK | -24.18% |
| 2018 Q4 | 20.54 Million SEK | 18.5% |
| 2018 FY | 20.54 Million SEK | -10.57% |
| 2018 Q2 | 22.86 Million SEK | 28.9% |
| 2018 Q1 | 17.74 Million SEK | -22.78% |
| 2017 Q4 | 22.97 Million SEK | 0.0% |
| 2017 FY | 22.97 Million SEK | -11.24% |
| 2017 Q1 | - SEK | 0.0% |
| 2016 FY | 25.88 Million SEK | 112.13% |
| 2015 FY | 12.2 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 84.798% |
| Ziccum AB (publ) | 6.38 Million SEK | -153.679% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -586.944% |
| BioArctic AB (publ) | 139.5 Million SEK | 88.384% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 53.169% |
| Mendus AB (publ) | 51.22 Million SEK | 68.365% |
| Genovis AB (publ.) | 98.04 Million SEK | 83.472% |
| Intervacc AB (publ) | 21.68 Million SEK | 25.254% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 39.325% |
| Active Biotech AB (publ) | 13.4 Million SEK | -20.933% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 86.929% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -0.546% |
| Aptahem AB (publ) | 8.99 Million SEK | -80.099% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 60.339% |
| Kancera AB (publ) | 17.97 Million SEK | 9.862% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 64.909% |
| Fluicell AB (publ) | 8.91 Million SEK | -81.772% |
| Saniona AB (publ) | 86.08 Million SEK | 81.175% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -214.172% |
| Biovica International AB (publ) | 34.76 Million SEK | 53.39% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -38.884% |
| AcouSort AB (publ) | 10.37 Million SEK | -56.148% |
| Xintela AB (publ) | 14.01 Million SEK | -15.626% |
| Abliva AB (publ) | 16.78 Million SEK | 3.432% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 92.449% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -40.073% |
| OncoZenge AB (publ) | 1.69 Million SEK | -853.796% |
| Amniotics AB (publ) | 10.54 Million SEK | -53.646% |
| 2cureX AB (publ) | 2.93 Million SEK | -452.129% |
| CombiGene AB (publ) | 4.15 Million SEK | -289.918% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -266.132% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 98.965% |
| Camurus AB (publ) | 414.81 Million SEK | 96.093% |
| Corline Biomedical AB | 6.78 Million SEK | -138.695% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 73.589% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 15.44% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 98.634% |
| Cyxone AB (publ) | 4.69 Million SEK | -245.228% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -21.586% |
| Biosergen AB | 5.08 Million SEK | -218.682% |
| Cantargia AB (publ) | 54.97 Million SEK | 70.52% |
| NextCell Pharma AB | 13.68 Million SEK | -18.379% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 77.446% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -17.67% |
| Nanologica AB (publ) | 79.32 Million SEK | 79.572% |
| SynAct Pharma AB | 51.83 Million SEK | 68.737% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -103.862% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -211.938% |
| LIDDS AB (publ) | 3.75 Million SEK | -331.443% |
| Lipum AB (publ) | 7.53 Million SEK | -114.977% |
| BioInvent International AB (publ) | 90.45 Million SEK | 82.085% |
| Alzinova AB (publ) | 9.33 Million SEK | -73.668% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 91.076% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -803.289% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 12.377% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -322.225% |
| Simris Alg AB (publ) | 148.93 Million SEK | 89.12% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 77.214% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 96.639% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -27.158% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -123.209% |